Streetbeat News

SIEN

Sientra Inc

http://sientra.com/

CEO

Jeffrey Nugent

Employees

234

Industry

Surgical and Medical Instrument Manufacturing

medical devices- plastic surgery: aesthetic and reconstructive, urology

Open

0.18

Mkt cap

2.1M

Volume

3.3M

High

0.20

P/E Ratio

-0.03

52-wk high

4.94

Low

0.16

Div yield

N/A

52-wk low

0.16

Trading of Sientra Inc. shares has resumed, indicating a return to normal trading activities for the company.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 3:20 pm

Shares of Sientra (SIEN) were halted on a circuit breaker due to a significant upward movement, with the stock now up 133.3%.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 3:15 pm

Health care stocks experienced significant movements in Wednesday's intraday session, with notable gainers including Cogent Biosciences, Larimar Therapeutics, BioXcel Therapeutics, Greenwich LifeSciences, Electromed, and Puma Biotechnology. On the losing end, Anitra, QuidelOrtho, NeuroOne Medical Tech, Renalytix, Sientra, and Sunshine Biopharma saw declines. Earnings reports influenced some of these movements.

Portfolio Pulse from Benzinga Insights

February 14, 2024 | 5:31 pm

U.S. stocks traded lower with the Dow Jones, NASDAQ, and S&P 500 all experiencing declines. Marriott International reported mixed Q4 results and provided FY24 earnings guidance below estimates. Beamr Imaging, Whole Earth Brands, and Digital Brands Group saw significant stock price increases, while Sunshine Biopharma, BIOLASE, and Sientra experienced major drops. The energy sector saw a minor decline, and real estate shares dipped more significantly.

Portfolio Pulse from Avi Kapoor

February 13, 2024 | 7:26 pm

IPG Photonics Corporation's shares fell by 11% after reporting mixed Q4 financial results and soft Q1 guidance. Other stocks showed significant movements, with notable gainers including Ohmyhome Limited, BioNexus Gene Lab Corp, and Digital Brands Group, Inc., among others. Losers included BIOLASE, Inc., Sunshine Biopharma, Inc., and Sientra, Inc., with significant drops after various announcements.

Portfolio Pulse from Avi Kapoor

February 13, 2024 | 6:13 pm

In Tuesday's intraday session, several health care stocks experienced significant movements. Notably, FibroBiologics, Candel Therapeutics, and Bicycle Therapeutics saw substantial gains, while Sunshine Biopharma, Biolase, and Sientra faced steep declines. The movements reflect varying market valuations and investor reactions to company-specific news or broader sector trends.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 5:31 pm

Sientra shares are trading lower following the company's announcement that it has filed for Chapter 11 bankruptcy protection in the United States Bankruptcy Court.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 5:12 pm

U.S. stocks traded lower with the Nasdaq Composite down over 1%. Coca-Cola (KO) reported better-than-expected Q4 sales, forecasting 6%-7% organic revenue growth for FY 2024. Beamr Imaging (BMR), Whole Earth Brands (FREE), and Digital Brands Group (DBGI) saw significant stock price increases. Conversely, Sunshine Biopharma (SBFM), BIOLASE (BIOL), and Sientra (SIEN) experienced substantial declines. Gold fell 1.4%, while oil prices rose.

Portfolio Pulse from Avi Kapoor

February 13, 2024 | 5:06 pm

U.S. stocks traded lower with the Dow Jones falling over 300 points due to a slowdown in annual inflation to 3.1% in January, higher than market estimates. Utilities shares rose by 1.1%, while information technology shares fell by 0.8%. Notable movements included Ohmyhome Limited (OMH), BioNexus Gene Lab Corp. (BGLC), and Digital Brands Group, Inc. (DBGI) experiencing significant gains, whereas Sunshine Biopharma, Inc. (SBFM), BIOLASE, Inc. (BIOL), and Sientra, Inc. (SIEN) saw sharp declines.

Portfolio Pulse from Avi Kapoor

February 13, 2024 | 2:43 pm

Sientra, Inc. is pursuing a sale through a voluntary Chapter 11 bankruptcy process, planning to use its cash reserves and $22.5 million in new debtor-in-possession financing from existing lenders. This financing includes a 'roll up' of $67.5 million of prepetition debt. The company aims to continue its operations during this process.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 1:37 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.